K Budde

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. ncbi FTY720 (fingolimod) in renal transplantation
    Klemens Budde
    Department of Nephrology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Clin Transplant 20:17-24. 2006
  2. ncbi Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study
    K Budde
    Department of Nephrology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Am J Transplant 12:1528-40. 2012
  3. ncbi Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition
    Klemens Budde
    Department of Nephrology, Charite Universitatsmedizin Berlin, Germany
    Am J Kidney Dis 59:276-83. 2012
  4. ncbi Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)
    Hans Peter Tony
    Department Medicine Rheumatology and Clinical Immunology, Charite Universitatsmedizin Berlin, Schumannstr 20 21, 10098 Berlin, Germany
    Arthritis Res Ther 13:R75. 2011
  5. ncbi Enteric-coated mycophenolate sodium
    Klemens Budde
    Clinical Transplant Programme and Department of Nephrology, Charite Universitatsmedizin Berlin, Campus Charite Mitte, Chariteplatz 1, Berlin, Germany
    Expert Opin Drug Saf 9:981-94. 2010
  6. ncbi Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients
    Klemens Budde
    Department of Nephrology, Charite University Hospital, Schumannstrasse 20 21, D 10117 Berlin, Germany
    Nephrol Dial Transplant 19:2606-14. 2004
  7. ncbi [Modern immunosuppression following renal transplantation. Standard or tailor made?]
    K Budde
    Medizinische Klinik m S Nephrologie, Campus Mitte, Charite Universitatsmedizin Berlin, Schumannstrasse 20 21, 10117 Berlin
    Urologe A 45:9-17. 2006
  8. ncbi Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic)
    K Budde
    Department of Nephrology, Campus Charité Mitte Charité, Humboldt University, Berlin, Germany
    Clin Nephrol 66:103-11. 2006
  9. ncbi Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients
    K Budde
    Department of Nephrology, Charite Universitatsmedizin Berlin, Schumannstr 20 21, 10098 Berlin, Germany
    Am J Transplant 7:888-98. 2007
  10. ncbi Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients
    K Budde
    Department of Nephrology, Charite University, Berlin, Germany
    Am J Transplant 10:571-81. 2010

Detail Information

Publications140 found, 100 shown here

  1. ncbi FTY720 (fingolimod) in renal transplantation
    Klemens Budde
    Department of Nephrology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Clin Transplant 20:17-24. 2006
    ....
  2. ncbi Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study
    K Budde
    Department of Nephrology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Am J Transplant 12:1528-40. 2012
    ..There was a significantly higher rate of rejection in the everolimus arm but this did not exert a deleterious effect by 3 years posttransplant...
  3. ncbi Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition
    Klemens Budde
    Department of Nephrology, Charite Universitatsmedizin Berlin, Germany
    Am J Kidney Dis 59:276-83. 2012
    ....
  4. ncbi Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)
    Hans Peter Tony
    Department Medicine Rheumatology and Clinical Immunology, Charite Universitatsmedizin Berlin, Schumannstr 20 21, 10098 Berlin, Germany
    Arthritis Res Ther 13:R75. 2011
    ....
  5. ncbi Enteric-coated mycophenolate sodium
    Klemens Budde
    Clinical Transplant Programme and Department of Nephrology, Charite Universitatsmedizin Berlin, Campus Charite Mitte, Chariteplatz 1, Berlin, Germany
    Expert Opin Drug Saf 9:981-94. 2010
    ..Mycophenolic acid (MPA) therapy is a fundamental component of most post-transplant immunosuppressive regimens. Side effects, however, are common and frequently necessitate dose reductions or discontinuations...
  6. ncbi Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients
    Klemens Budde
    Department of Nephrology, Charite University Hospital, Schumannstrasse 20 21, D 10117 Berlin, Germany
    Nephrol Dial Transplant 19:2606-14. 2004
    ..Current immunosuppressant regimens need to be improved to prevent acute and chronic graft rejection. The novel macrocyclic immunosuppressant everolimus (Certican, RAD) is currently in clinical development to address this issue...
  7. ncbi [Modern immunosuppression following renal transplantation. Standard or tailor made?]
    K Budde
    Medizinische Klinik m S Nephrologie, Campus Mitte, Charite Universitatsmedizin Berlin, Schumannstrasse 20 21, 10117 Berlin
    Urologe A 45:9-17. 2006
    ..Altogether, these measures as well as optimized supportive therapy will help to further improve the longevity of the transplanted organ...
  8. ncbi Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic)
    K Budde
    Department of Nephrology, Campus Charité Mitte Charité, Humboldt University, Berlin, Germany
    Clin Nephrol 66:103-11. 2006
    ..The aim of the extension study was to collect long-term safety and efficacy data on EC-MPS, and to confirm the safety of conversion from MMF to EC-MPS in a larger patient population...
  9. ncbi Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients
    K Budde
    Department of Nephrology, Charite Universitatsmedizin Berlin, Schumannstr 20 21, 10098 Berlin, Germany
    Am J Transplant 7:888-98. 2007
    ..In conclusion, equimolar doses of EC-MPS and MMF produce equivalent MPA exposure, while the delayed release formulation of EC-MPS exhibits more variable predose levels and T(max). Overall, IMPDH activity reflected MPA pharmacokinetics...
  10. ncbi Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients
    K Budde
    Department of Nephrology, Charite University, Berlin, Germany
    Am J Transplant 10:571-81. 2010
    ..The initial sotrastaurin + tacrolimus regimen was efficacious and well tolerated but the postconversion sotrastaurin + MPA regimen showed inadequate efficacy. Longer-term evaluation of sotrastaurin + tacrolimus is warranted...
  11. ncbi Review of the immunosuppressant enteric-coated mycophenolate sodium
    Klemens Budde
    Humboldt University, Department of Nephrology, Charite, Campus Charite Mitte, Schumannstrasse, D 10117 Berlin, Germany
    Expert Opin Pharmacother 5:1333-45. 2004
    ..EC-MPS therefore presents physicians and patients with a valid alternative MPA therapy with a comparable efficacy and safety profile to MMF...
  12. ncbi Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial
    Klemens Budde
    Department of Nephrology, Charite University, Berlin, Germany
    Lancet 377:837-47. 2011
    ..Immunosuppression based on the mammalian-target-of-rapamycin inhibitor everolimus was assessed as a strategy for elimination of calcineurin-inhibitor exposure and optimisation of renal-graft function while maintaining efficacy...
  13. ncbi Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients
    K Budde
    University Hospital Charite, Berlin, Germany
    Transplant Proc 36:524S-527S. 2004
    ..5% vs MMF: 12.3%; P=ns). These data demonstrate that stable renal transplant recipients receiving MMF can be converted to EC-MPS with no efficacy or tolerability compromise...
  14. ncbi Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study
    Klemens Budde
    University Hospital Charite, Berlin, Germany
    Am J Transplant 4:237-43. 2004
    ..8%; MMF 4.9%; p=NS) were observed in both groups. In conclusion, renal maintenance patients can be converted from MMF to EC-MPS without compromising the safety and efficacy profile associated with MMF...
  15. ncbi Proposal for guidelines for publication of randomized trials in the American Journal of Transplantation
    Klemens Budde
    Department of Nephrology, , Campus Mitte, Humboldt University, 10098 Berlin, Germany
    Am J Transplant 5:644-7. 2005
  16. ncbi Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study
    K Budde
    Universitätetsklinik Charité, Berlin, Germany
    Transplant Proc 37:912-5. 2005
    ..The results of this study demonstrate the long-term safety of EC-MPS and reconfirm the safety of converting MMF maintenance renal transplant patients to EC-MPS...
  17. ncbi Improved rejection prophylaxis with an initially intensified dosing regimen of enteric-coated mycophenolate sodium in de novo renal transplant recipients
    Klemens Budde
    Department of Nephrology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Transplantation 92:321-7. 2011
    ..Approximately half of cyclosporine A-treated renal transplant recipients do not reach sufficient mycophenolic acid (MPA) exposure in the first weeks posttransplantation with standard MPA dosing regimens...
  18. ncbi Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring
    Klemens Budde
    Department of Nephrology, University Hospital Charite, Berlin, Germany
    Ther Drug Monit 29:381-4. 2007
    ..Physicians targeting a certain MPA predose level have to be aware of the higher morning C0 levels with EC-MPS, whereas the overall MPA exposure is not different to MMF...
  19. ncbi Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients
    K Budde
    Department of Nephrology, Charite University Hospital, Schumannstr 20 21, D 10117 Berlin, Germany
    Eur J Med Res 10:169-74. 2005
    ..There was no effect of common demographic parameters (age, sex, weight) on variability in steady-state exposure. These results support the clinical use of everolimus in renal transplantation...
  20. ncbi Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab
    K Budde
    Department of Nephrology, Campus Charité Mitte Charité, Universitatsmedizin Berlin, Schumannstrasse 20 21, 10117 Berlin, Germany
    Clin Nephrol 67:164-75. 2007
    ..The lower limit of exposure to calcineurin inhibitors has not yet been established in de novo renal transplant patients receiving mycophenolic acid therapy with basiliximab...
  21. ncbi Pharmacokinetic principles of immunosuppressive drugs
    Klemens Budde
    Department of Nephrology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Ann Transplant 13:5-10. 2008
    ..Future studies have to take these considerations into account in order to better guide immunosuppression towards a more individualized therapy, which remains an important goal in transplant medicine...
  22. ncbi Pharmacodynamic monitoring of mycophenolate mofetil
    K Budde
    Department of Internal Medicine Nephrology, Humboldt University, Berlin, Germany
    Clin Chem Lab Med 38:1213-6. 2000
    ..The interindividual variability of IMPDH activity may account for pharmacodynamic differences in MMF-treated patients. Based on pharmacodynamic monitoring better dosing strategies for MMF-treated patients may evolve...
  23. ncbi Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes
    Klemens Budde
    Department of Nephrology, University Hospital Charite, Berlin, Germany
    Transplantation 83:417-24. 2007
    ....
  24. ncbi First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients
    Klemens Budde
    Department of Nephrology, University Hospital Charite, Schumannstrasse 20 21, 10117 Berlin, Germany
    J Am Soc Nephrol 13:1073-83. 2002
    ..Transient, but asymptomatic bradycardia was the most common adverse event. The long t(1/2) suggests less frequent dosing intervals. The size of V(d)/F is in excess of blood volume, consistent with widespread tissue distribution..
  25. ncbi Problems of cyclosporine absorption profiling using C2-monitoring
    M Schuetz
    Department of Nephrology, Charite, Schumannstr 20 21, D 10117 Berlin, Germany
    Eur J Med Res 10:175-8. 2005
    ..A significant proportion of patients are poor and/or slow absorbers. CsA toxicity may not be detected by C2 monitoring alone. With the use of basiliximab and mycophenolatesodium lower target levels seem to be sufficient...
  26. ncbi Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients
    K Budde
    Department of Internal Medicine-Nephrology, , Campus Mitte, Humboldt University, Schumannstrasse 20/21, 10098 Berlin, Germany
    Transplant Proc 34:1748-50. 2002
  27. ncbi Cyclosporin C2hour monitoring after renal transplantation
    G Einecke
    Medizinische Klinik mit Schwerpunkt Nephrologie, Charite, Humboldt Universitat, Berlin, Germany
    Int J Clin Pharmacol Ther 41:477-81. 2003
    ..Although mean C2hour levels do not seem to identify patients at risk of rejection, they may help to identify excessive immunosuppression and to improve long-term survival by reducing CsA toxicity...
  28. ncbi Effect of mycophenolate mofetil monotherapy on T-cell functions and inosine monophosphate dehydrogenase activity in patients undergoing a kidney transplantation
    N Kamar
    Department of Nephrology, Charite Hospital, Berlin, Germany
    Transplant Proc 38:2292-4. 2006
    ..In conclusion, administration of 1 g of MMF was associated with a transient decrease in CD25 expression in addition to a temporary dramatic decrease in both T-cell proliferation and IMPDH activity...
  29. ncbi FTY 720A mediates reduction of lymphocyte counts in human renal allograft recipients by an apoptosis-independent mechanism
    T Bohler
    Department of Nephrology, Humboldt University Berlin, Germany
    Transpl Int 13:S311-3. 2000
    ..We detected no significant difference in apoptosis rates between patients who received placebo or FTY 720A. However, in vitro experiments showed that high concentrations of FTY 720 A induced apoptosis in human PBMC...
  30. ncbi Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients
    P Glander
    Department of Internal Medicine, Nephrology, Charite Campus Mitte, Humboldt University, Berlin, Germany
    Int J Clin Pharmacol Ther 41:470-6. 2003
    ....
  31. ncbi Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells
    P Glander
    Department of Internal Medicine, Nephrology, University Medical Center Charite, Campus Mitte, Humboldt University, Schumannstr 20 21, 10098 Berlin, Germany
    Clin Biochem 34:543-9. 2001
    ..It was the aim of this study to develop a nonradioactive method for specific measurement of IMPDH activity in isolated peripheral mononuclear cells (MNC)...
  32. ncbi The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy
    Stephanie Kramer
    Department of Nephrology and Center for Cardiovascular Research, Charite Universitatsmedizin Berlin, Charite Campus Mitte, Humboldt University Berlin, D 10117 Berlin, Germany
    Am J Physiol Renal Physiol 297:F218-27. 2009
    ..These results suggest that infiltrating lymphocytes play an active, profibrotic role in the progression of hypertensive renal tissue injury...
  33. ncbi Arrival time parametric imaging: a new ultrasound technique for quantifying perfusion of kidney grafts
    T Fischer
    Dept of Radiology, Charite Universitatsmedizin Berlin, Campus Charite Mitte
    Ultraschall Med 29:418-23. 2008
    ..Evaluation of a new standardised ultrasound (US) technique for diagnosis of acute rejection of kidney grafts...
  34. ncbi Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptor
    D Dragun
    , Berlin, Germany
    Transplant Proc 35:2104-5. 2003
  35. ncbi Prognostic value of the Banff classification
    J Waiser
    Department of Internal Medicine Nephrology, Humboldt University, Berlin, Germany
    Transpl Int 13:S106-11. 2000
    ..4%, P < 0.0001). Conclusions: (1). The Banff classification is a predictive parameter for renal allograft survival. (2). Certain characteristics predispose patients to certain biopsy findings...
  36. ncbi Prospective randomized pilot study of steroid withdrawal with mycophenolate mofetil in long-term cyclosporine-treated patients: 4-year follow-up
    K Budde
    Department of Internal Medicine-Nephrology, Charit, Humboldt University, Schumannstrasse 20/21, Berlin 10098, Germany
    Transplant Proc 34:1703-5. 2002
  37. ncbi Laparoscopic versus open donor nephrectomy in Germany: impact on donor health-related quality of life and willingness to donate
    M Giessing
    Department of Urology, Charité University Hospital CCM of Humboldt University Berlin, Schumannstrasse 20 21, D 10098 Berlin, Germany
    Transplant Proc 37:2011-5. 2005
    ..We therefore performed a study with two questionnaires (SF-36/GBB-24) and one set of open questions for all donors in our department...
  38. ncbi Pharmacokinetics and pharmacodynamics of mycophenolate mofetil under oral and intravenous therapy
    K-P Braun
    Department of Internal Medicine-Nephrology, , Campus Mitte, Humboldt University, Schumannstrasse 20/21, 10098 Berlin, Germany
    Transplant Proc 34:1745-7. 2002
  39. ncbi Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat
    Stephanie Kramer
    Department of Nephrology and Center for Cardiovascular Research, Charite Universitatsmedizin Berlin, Charite Campus Mitte, Humboldt University, Berlin, Germany
    Am J Physiol Renal Physiol 294:F440-9. 2008
    ..e., proteinuria, extracellular matrix accumulation, renal cell proliferation, and inflammatory cell infiltration...
  40. ncbi Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation
    L Liefeldt
    Department of Nephrology, Charite Campus Mitte, Charite Universitatsmedizin Berlin, Berlin, Germany
    Am J Transplant 12:1192-8. 2012
    ..This single center analysis demonstrates for the first time that everolimus-based immunosuppression is associated with an increased risk for the development of DSA and AMR...
  41. ncbi Practice variations in the evaluation of adult candidates for cadaveric kidney transplantation: a survey of the European Transplant Centers
    L Fritsche
    Department of Nephrology, University Hospital Charite, Berlin, Germany
    Transplantation 70:1492-7. 2000
    ....
  42. ncbi [Ten years of laparoscopic living kidney donation. From an extravagant to a routine procedure]
    M Giessing
    Klinik für Urologie, Campus Mitte, Charite Universitatsmedizin Berlin, Schumannstrasse 20 21, 10098 Berlin
    Urologe A 45:46-52. 2006
    ..For the operating surgeon multiple developments have expanded the technical armentarium. LDN is safe for donor, recipient and kidney. Central issue of an optimal LDN is sufficient experience with laparoscopic urological techniques...
  43. ncbi Five year outcome of tacrolimus rescue therapy in late rejection after renal transplantation
    K Budde
    Department of Nephrology, Charit, Humboldt University, Berlin, Germany
    Transplant Proc 34:1594-6. 2002
  44. ncbi Pharmacodynamics of FTY720, the first member of a new class of immune-modulating therapeutics in transplantation medicine
    T Bohler
    Department of Internal Medicine, Nephrology, Charite, Campus Mitte, Humboldt University, Berlin, Germany
    Int J Clin Pharmacol Ther 41:482-7. 2003
    ..Further studies are necessary to investigate the mechanism of action of FTY in detail...
  45. ncbi FTY720: early clinical experience
    D Dragun
    University Hospital Charit, Department of Nephrology, Campus Mitte, Berlin, Germany
    Transplant Proc 36:544S-548S. 2004
    ....
  46. ncbi [A new method for standardized diagnosis following renal transplantation. Ultrasound with contrast enhancement]
    T Fischer
    Institut fur Radiologie, Universitatsklinikum Charite, Campus Mitte, Universitatsmedizin, Schumannstrtasse 20 21, 10098 Berlin
    Urologe A 45:38-45. 2006
    ..This method is also helpful to detect and control acute rejections and to better visualize hematomas, deficits of perfusion, and tumors...
  47. ncbi Cyclosporine absorption profiling and therapeutic drug monitoring using C(2) blood levels in stable renal allograft recipients
    G Einecke
    Department of Nephrology, , Schumannstrasse 20/20, 10098 Berlin, Germany
    Transplant Proc 34:1738-9. 2002
  48. ncbi Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients
    Claudia Sommerer
    Department of Nephrology, University Hospital, Heidelberg, Germany
    Br J Clin Pharmacol 69:346-57. 2010
    ..Pharmacokinetic (PK) and pharmacodynamic (PD) monitoring strategies and clinical outcome were evaluated in enteric-coated mycophenolate sodium (EC-MPS)-treated renal allograft recipients...
  49. ncbi Target enzyme activity as a biomarker for immunosuppression
    Petra Glander
    Department of Nephrology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Ther Drug Monit 32:257-60. 2010
    ..Although the determination of target enzyme activity, eg, by the determination of IMPDH activity, holds promise for a more individualized therapy in transplant medicine, more studies are needed to prospectively validate this approach...
  50. ncbi Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients
    Torsten Bohler
    Department of Internal Medicine Nephrology, Charite Campus Mitte, Humboldt University, Berlin, Germany
    Int Immunopharmacol 7:88-95. 2007
    ..In conclusion FTY720 treatment reduces B-cells expressing CD62L to a significant lesser degree than T-cells expressing CD62L...
  51. ncbi Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantation
    Nassim Kamar
    Department of Nephrology, Charite Universitaetsmedizin Berlin, Berlin, Germany
    Clin J Am Soc Nephrol 4:936-42. 2009
    ....
  52. ncbi Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients
    Klemens Budde
    University Clinic Charit, Berlin, Germany
    J Clin Pharmacol 45:781-91. 2005
    ..In conclusion, these results suggest that steady-state everolimus exposure over the wide range assessed in this study did not affect steady-state cyclosporine pharmacokinetics...
  53. ncbi Accurate prediction of kidney allograft outcome based on creatinine course in the first 6 months posttransplant
    L Fritsche
    Dept Nephrology, Charite, Berlin, Germany
    Transplant Proc 37:731-3. 2005
    ..These patients may benefit from therapeutic measures tailored for this high-risk setting...
  54. ncbi Differences in reporting of acute rejections between American and European publications of large immunosuppressive trials impair comparability of study results
    F Fleiner
    Department of Nephrology, University Hospital Charite, Campus Mitte, Schumannstrasse 20 21, 10098 Berlin, Germany
    Transplant Proc 37:2048-50. 2005
    ..5% vs E: 26.5%). Our systematic review showed large discrepancies with a trend to report biopsy-proven rejection rates only in recent years...
  55. ncbi Different diagnostic approaches to adult candidates for cadaveric kidney transplantation in Europe
    L Fritsche
    Med Klinik m S Nephrologie, Universitatsklinikum Charite, Berlin, Germany
    Transpl Int 13:S263-6. 2000
    ..There are significant differences in the evaluation of renal transplant candidates across Europe. In some parts of Europe transplant candidates are either investigated more discriminately or less comprehensively than in other regions...
  56. ncbi Reactivation of tuberculosis after conversion from azathioprine to mycophenolate mofetil 16 years after renal transplantation
    J Waiser
    Department of Nephrology, University Hospital Charite, Campus Charite Mitte, Humboldt University, Berlin, Germany
    Am J Kidney Dis 35:E12. 2000
    ..We conclude that MMF therapy in renal allograft recipients may cause reactivation of old dormant tuberculosis, even in the very late posttransplantation period. In these patients, close monitoring and isoniazid prophylaxis may be useful...
  57. ncbi Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression
    R Trappe
    Department of Hematology, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Berlin, Germany
    Am J Transplant 9:2331-7. 2009
    ..The immunosuppressive effect of single agent rituximab may partially compensate the negative impact of IR on the graft function. Thus, it is possible to reduce immunosuppression when using chemotherapy to treat PTLD...
  58. ncbi Treating type 2 diabetes in renal insufficiency: the role of pioglitazone
    L Fritsche
    Department of Nephrology, Charite Campus Mitte, Berlin, Germany
    Int J Clin Pharmacol Ther 41:488-91. 2003
    ..Although there are possible side effects (mainly fluid retention and weight gain and--very rarely--hepatotoxicity). Pioglitazone has a good safety profile in diabetic patients with impaired renal function...
  59. ncbi FTY720 alters the composition of T-lymphocyte subpopulations in the peripheral blood compartment of renal transplant patients
    T Boehler
    Department of Nephrology, Charit, , Humboldt-University, Berlin, Germany
    Transplant Proc 34:2242-3. 2002
  60. ncbi Successful steroid withdrawal at the end of the 1st year after renal transplantion in mycophenolate mofetil-treated patients
    K Budde
    Department of Internal Medicine-Nephrology, Charit, Humboldt University, Schumannstrasse 20/21, Berlin 10098, Germany
    Transplant Proc 34:1700-2. 2002
  61. ncbi Why rejections are not biopsy proven: frequency and reasons
    F Fleiner
    Department of Nephrology, Charite Campus Mitte, Schumannstrasse 20 21, 10098 Berlin, Germany
    Transplant Proc 42:4509-12. 2010
    ..Additionally, we analyzed our own population, which has a clearly defined biopsy strategy, to further investigate the rate of non-BPAR in routine clinical practice...
  62. ncbi Impact of cyclosporine on the development of immunosuppressive therapy
    L Fritsche
    Department of Nephrology, Charite Campus Mitte, Berlin, Germany
    Transplant Proc 36:130S-134S. 2004
    ..With other trials evaluating the impact of Neoral in combination with newer therapies such as Certican, myfortic, and FTY720, the use of CsA in transplant recipients looks set to continue...
  63. ncbi Quality of life of living kidney donors in Germany: a survey with the Validated Short Form-36 and Giessen Subjective Complaints List-24 questionnaires
    Markus Giessing
    Department of Urology, Charite University Hospital, Campus Mitte, Berlin, Germany
    Transplantation 78:864-72. 2004
    ..Most studies evaluating the impact of kidney donation on donors' quality of life (QOL) have limitations such as small cohort size, unmatched references, use of nonstandardized and nonvalidated questionnaires, or low response rates...
  64. ncbi Laparoscopic donor nephrectomy in Germany
    M Giessing
    Department of Urology, , Berlin, Germany
    Transplant Proc 34:3099-101. 2002
  65. ncbi S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis
    Sebastian Martini
    Department of Nephrology, Charite Universitatsmedizin Berlin, Charite Campus Mitte, Humboldt University, Berlin, Germany
    Am J Physiol Renal Physiol 292:F1761-70. 2007
    ..Our study expands on findings on FTY720's beneficial effects on tubulointerstitial and functional disease progression previously reported in anti-thy1-induced chronic glomerulosclerosis...
  66. ncbi Limitations of C2 monitoring in renal transplant recipients
    Gunilla Einecke
    Department of Nephrology, Charite, Berlin, Germany
    Nephrol Dial Transplant 20:1463-70. 2005
    ..The present study sought to validate the cornerstones of the current concept of C(2) monitoring...
  67. ncbi Impact of PGE1 on cyclosporine A induced up-regulation of TGF-beta1, its receptors, and related matrix production in cultured mesangial cells
    Kerstin Dell
    Department of Internal Medicine Nephrology, University Hospital Charite, Campus Mitte, Humboldt University, Schumannstrasse 20 21, 10117 Berlin, Germany
    Cytokine 22:189-93. 2003
    ..In vivo studies will show, whether treatment with PGE1 analogues will be useful in preventing CsA induced glomerulosclerosis...
  68. ncbi Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients
    Klemens Budde
    Department of Nephrology, , Berlin, Germany
    Am J Transplant 3:846-54. 2003
    ..These data show that FTY720 is highly effective in humans, with single oral doses of FTY720 ranging from 0.25 to 3.5 mg causing a reversible selective panlymphopenia...
  69. ncbi Reduction of gastrointestinal complications in renal graft recipients after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium
    P Reinke
    Department of Nephrology, University Hospital Charite, Berlin, Germany
    Transplant Proc 43:1641-6. 2011
    ..In conclusion, conversion from MMF to EC-MPS reduces GI complications in renal graft recipients, reduces the patients' physical discomfort, and maintains their quality of life. (ClinicalTrials.gov number NCT00149968.)...
  70. ncbi De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection
    J Waiser
    Pathology, University Hospital Charite, Berlin, Germany
    Am J Kidney Dis 34:556-9. 1999
    ..However, because antiviral therapy with ganciclovir was started before the onset of HUS in both patients, we cannot definitely rule out that HUS was triggered by ganciclovir...
  71. ncbi Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil
    J Waiser
    Department of Nephrology, University Hospital Charite, Berlin, Germany
    Am J Kidney Dis 34:e9. 1999
    ..Subsequently, anti-proteinase-3-titer (anti-Pr3-titer) returned to normal and renal function improved. In conclusion, MMF in combination with corticosteroids may be useful in the treatment of acute c-ANCA-positive vasculitis...
  72. ncbi TNF-alpha and IL-1alpha induce apoptosis in subconfluent rat mesangial cells. Evidence for the involvement of hydrogen peroxide and lipid peroxidation as second messengers
    T Bohler
    Department of Internal Medicine Nephrology, Humboldt University, Charite, Berlin, Germany
    Cytokine 12:986-91. 2000
    ..Increased c-jun expression may be a downstream intracellular signal of TNF-alpha-, but not IL-1alpha-induced apoptosis...
  73. ncbi MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients
    Ingrid Mai
    , , Schumannstr. 20/21, 10098 Berlin, Germany
    J Clin Pharmacol 43:1101-7. 2003
    ..5-37.1) in the noncarrier group. It was concluded that MDR1 haplotypes derived from the SNPs 2677G>T (exon 21) and 3435C>T (exon 26) are not associated with cyclosporine pharmacokinetics in renal transplant patients...
  74. ncbi No association between renin-angiotensin system gene polymorphisms and early and long-term allograft dysfunction in kidney transplant recipients
    Torsten Slowinski
    Center for Cardiovascular Research, Klinik für Nephrologie, Charite, Humboldt Universitat, Berlin, Germany
    Nephrol Dial Transplant 19:2846-51. 2004
    ..We determined if gene polymorphisms of the RAS are associated with early and long-term post-transplantation graft dysfunction in 405 Caucasian kidney recipients with graft survivals of >2 years...
  75. ncbi Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials
    Frank Pietruck
    Department of Nephrology, University Hospital Essen, Essen, Germany
    Clin Transplant 21:117-25. 2007
    ..Moreover, diabetic patients can apparently be safely converted from MMF to EC-MPS. More data from prospective studies are needed to fully judge the efficacy and safety profile of EC-MPS in the diabetic transplant population...
  76. ncbi [Evaluation and follow-up of living kidney donors]
    M Giessing
    Universitatsklinik fur Urologie, Charite, Berlin, Germany
    Dtsch Med Wochenschr 129:147-50. 2004
    ..Also, psychological counselling should be offered. The aim is to minimize risks for the single kidney and to recognize early potentially kidney damaging affections...
  77. ncbi [Kidney donors and kidney transplantation in the elderly]
    M Giessing
    Klinik und Poliklinik für Urologie Campus Mitte, Charite Universitatsmedizin Berlin
    Urologe A 43:947-54. 2004
    ..Nevertheless, the role of HLA-matching should be reconsidered to reduce rejections...
  78. ncbi [Treatment of hypercholesterolemia in kidney transplant recipients]
    L Fritsche
    Med. Klinik mit Schwerpunkt Nephrologie, , Berlin
    Dtsch Med Wochenschr 128:879-81. 2003
  79. ncbi Living donor nephrectomy--no impact of genetic relationship
    M Giessing
    Department of Urology, University Hospital, Charite University Berlin, Schumanstrasse 20 21, D 10098 Berlin, Germany
    Transplant Proc 35:2860-2. 2003
    ..A retrospective, single-center analysis was conducted to compare the results of living donor kidney transplantation between living unrelated (LURD) and living related (LRD) donors...
  80. ncbi 20-year experience with elderly donors in living renal transplantation
    M Giessing
    Department of Urology, University Hospital, Charite University Berlin, Schumanstrasse 20 21, D 10098 Berlin, Germany
    Transplant Proc 35:2855-7. 2003
    ..This study evaluates the impact of living renal donors (LD) aged 60 years and older on graft performance and patient survival in an old-for-young constellation...
  81. ncbi [Contraindications to living donor kidney transplantation]
    L Liefeldt
    Medizinische Klinik mit Schwerpunkt Nephrologie
    Dtsch Med Wochenschr 130:2039-42. 2005
  82. ncbi The use of contrast-enhanced US in renal transplant: first results and potential clinical benefit
    Thomas Fischer
    Department of Radiology, Universitatsmedizin Berlin, Campus Charite Mitte, Schumannstrasse 20 21, 10098 Berlin, Germany
    Eur Radiol 15:E109-16. 2005
    ....
  83. ncbi Attitude to nephrolithiasis in the potential living kidney donor: a survey of the German kidney transplant centers and review of the literature
    Markus Giessing
    Department of Urology, Charite Universitatsmedizin Berlin, Germany
    Clin Transplant 22:476-83. 2008
    ..For almost all centers history of nephrolithiasis does not preclude living kidney donation. Stone composition proved to be of little relevance for decision making...
  84. ncbi Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria
    Fritz Diekmann
    Department of Nephrology, Charite Campus Mitte, Berlin, Germany
    Transpl Int 21:152-5. 2008
    ..Prognosis of chronic allograft dysfunction is poor. However, conversion to SRL remains an option for patients with low baseline proteinuria, which can slow down deterioration of graft function during a follow-up period of up to 5 years...
  85. ncbi Cross-over kidney transplantation with simultaneous laparoscopic living donor nephrectomy: initial experience
    Markus Giessing
    Department of Urology, Charite Campus Mitte, Universitatsmedizin Berlin, Berlin, Germany
    Eur Urol 53:1074-8. 2008
    ..Cross-over kidney transplantation should be encouraged. A databank on pairs willing to participate in organ exchange programs should be created...
  86. ncbi Testosterone concentrations and sirolimus in male renal transplant patients
    Lutz Fritsche
    Department of Nephrology, Charite Campus Mitte, Berlin, Germany
    Am J Transplant 4:130-1. 2004
    ..In contrast, FSH and LH concentrations were higher while prolactin levels were not different. These data are consistent with sirolimus-related testosterone suppression and suggest a need for further studies...
  87. ncbi The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients
    Timm H Westhoff
    Centrum 10 Nephrology, Charite Campus Benjamin Franklin, 12200 Berlin, Germany
    Nephrol Dial Transplant 22:2354-8. 2007
    ..Creatinine clearance, however, was significantly lower in FTY720-treated patients. In the present study, we examined the impact of FTY720 on vascular function in a subgroup of patients of this trial...
  88. ncbi The immunosuppressive potential of misoprostol--efficacy and variability
    Johannes Waiser
    Department of Internal Medicine Nephrology, University Hospital Charite, Campus Mitte, Humboldt University, Berlin, Germany
    Clin Immunol 109:288-94. 2003
    ..The considerable interindividual variability as well as gender-specific differences seem to account for the variability of clinical study results...
  89. ncbi "Old-for-old" cadaveric renal transplantation: surgical findings, perioperative complications and outcome
    Markus Giessing
    Universitätsklinik Charité Campus Mitte, Medizinische Fakultat der Humboldt Universitat zu Berlin, Klinik für Urologie, Schumanstrasse 20 21, D 10098 Berlin, Germany
    Eur Urol 44:701-8. 2003
    ....
  90. ncbi Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells
    Petra Glander
    Department of Internal Medicine, Nephrology, Campus Mitte, Charite Universitatsmedizin Berlin, Chariteplatz 1, Berlin 10098, Germany
    Ther Drug Monit 31:351-9. 2009
    ....
  91. ncbi Old-for-old kidney allocation allows successful expansion of the donor and recipient pool
    Lutz Fritsche
    Department of Nephrology, Campus Mitte, Berlin, Germany
    Am J Transplant 3:1434-9. 2003
    ..HLA-matching should not be ignored, as the risk of acute rejection in elderly patients is substantial...
  92. ncbi Immunohistochemical double-staining of renal allograft tissue: critical assessment of three different protocols
    Johannes Waiser
    Department of Internal Medicine Neophrology, University Hospital Charite, Campus Mitte, Humboldt University Schumannstrasse 20 21, 10117 Berlin, Germany
    Virchows Arch 440:648-54. 2002
    ..Thus, the use of primary antibodies from different species is by far the most reliable technique for quantitative double-staining analyses in renal allograft tissue...
  93. ncbi Cyclosporine A up-regulates the expression of TGF-beta1 and its receptors type I and type II in rat mesangial cells
    Johannes Waiser
    Department of Internal Medicine Nephrology, University Hospital Charite, Campus Charite Mitte, Humboldt University, Berlin, Germany
    Nephrol Dial Transplant 17:1568-77. 2002
    ..We investigated whether CsA up-regulates the expression of TGF-beta1 and its receptors type I (TbetaR-I) and type II (TbetaR-II) in cultured rat MCs, and whether this effect translates into enhanced matrix protein accumulation...
  94. ncbi Recognition of critical situations from time series of laboratory results by case-based reasoning
    Lutz Fritsche
    Department of Nephrology, Charite, Berlin, Germany
    J Am Med Inform Assoc 9:520-8. 2002
    ..To assess the potential of this approach for kidney transplant recipients, where recognition of acute rejections is based on the pattern of changes in serum creatinine...
  95. ncbi Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation
    Mareen Matz
    Med Klinik mS Nephrologie, Universitätsmedizin Charité, Berlin, Germany
    Expert Opin Drug Metab Toxicol 7:103-13. 2011
    ..There is a large need for new immunosuppressive agents that lack toxicity of current agents such as calcineurin inhibitors but show high synergistic efficiency in preventing rejection processes...
  96. ncbi Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients
    Steffen Bauer
    Institute of Clinical Pharmacology, University Medical Centre Charité, Humboldt University of Berlin, Berlin, Germany
    Br J Clin Pharmacol 55:203-11. 2003
    ..This study investigated the effects of St John's wort extract (SJW) on the pharmacokinetics and metabolism of the immunosuppressant cyclosporin A (CSA)...
  97. ncbi Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients
    Ingrid Mai
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Berlin, Germany
    Nephrol Dial Transplant 18:819-22. 2003
    ..This study investigated the effect of St John's wort (SJW) extract on the pharmacokinetics of the immunosuppressants tacrolimus (TAC) and mycophenolic acid (MPA)...
  98. ncbi Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients
    Petra Glander
    Department of Nephrology, Charite Universitatsmedizin Berlin, Chariteplatz 1, 10117 Berlin, Germany
    Clin J Am Soc Nephrol 5:503-11. 2010
    ....
  99. ncbi Effects of the new immunosuppressive agent AEB071 on human immune cells
    Mareen Matz
    Department of Nephrology, Universitätsmedizin Charité Campus Mitte, Chariteplatz 1, 10117 Berlin, Germany
    Nephrol Dial Transplant 25:2159-67. 2010
    ..We here present extensive in vitro studies that contribute to the understanding of AEB071 effects on human lymphocyte, natural killer (NK) cell and dendritic cell (DC) action...
  100. ncbi Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients
    Michael Duerr
    Department of Nephrology, Charite Universitatsmedizin Berlin, Chariteplatz 1, 10117 Berlin, Germany
    Clin J Am Soc Nephrol 5:703-8. 2010
    ..Hereditary defects, drugs, and food allergies may play a role in the development of angioedema. We systematically investigated the incidence of angioedema in renal allograft recipients treated with mTOR inhibitors (mTORis)...
  101. ncbi Gadolinium-enhanced three-dimensional magnetic resonance angiography versus conventional digital subtraction angiography: which modality is superior in evaluating living kidney donors?
    Markus Giessing
    Department of Urology, Charite University Hospital, Berlin, Germany
    Transplantation 76:1000-2. 2003
    ..The correct diagnosis of renal donor veins differed significantly in favor of MRA (kappa 0.79 vs. 0.45; P=0.008). MRA is superior to DSA in assessing the renal vasculature in living kidney donors...